The brain-penetrant mIDH1 inhibitor olutasidenib showed stable disease as a best response in 40% of recurrent/progressive IDH1-mutant glioma patients in a phase Ib/II trial43. This evidence concerns the gene IDH1 and central nervous system cancer.